NewLimit Raises $435 Million Series C To Bring Aging Reprogramming Medicine To Human Trials
By Amit Chowdhry ● Jun 7, 2026
NewLimit has announced a $435 million Series C led by Founders Fund, alongside new investors Thrive Capital, Greenoaks, and Quiet Capital, and returning investors Kleiner Perkins, Abstract, Nat Friedman and Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, Human Capital, and others. The raise will fund the company's first aging reprogramming medicine into human clinical trials next year, a timeline accelerated by the breakthrough discovery of a prototype medicine that reverses cell age in old human liver cells.NewLimit has announced a $435 million Series C led by Founders Fund, alongside new investors Thrive Capital, Greenoaks, and Quiet Capital, and returning investors Kleiner Perkins, Abstract, Nat Friedman and Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, Human Capital, and others. The raise will fund the company's first aging reprogramming medicine into human clinical trials next year, a timeline accelerated by the breakthrough discovery of a prototype medicine that reverses cell age in old human liver cells.